Relmada Therapeutics Reports Director/Officer Changes & Financials
Ticker: RLMD · Form: 8-K · Filed: Dec 15, 2025 · CIK: 1553643
| Field | Detail |
|---|---|
| Company | Relmada Therapeutics, Inc. (RLMD) |
| Form Type | 8-K |
| Filed Date | Dec 15, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $787,787, $827,176, $499,800, $524,790 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, corporate-governance, filing
Related Tickers: RLMD
TL;DR
Relmada (RLMD) filed an 8-K on 12/15/25 detailing director/officer changes and financials.
AI Summary
Relmada Therapeutics, Inc. filed an 8-K on December 15, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits, with the earliest reported event date being December 12, 2025.
Why It Matters
This 8-K filing indicates potential shifts in the company's leadership and governance, which could impact strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in directors or officers can signal internal shifts that may affect company strategy or stability.
Key Players & Entities
- RELMADA THERAPEUTICS, INC. (company) — Registrant
- December 12, 2025 (date) — Earliest event reported
- December 15, 2025 (date) — Filing date
FAQ
What specific roles have seen departures or appointments?
The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' but does not specify the exact roles in the provided text.
Are there any new directors or officers elected or appointed?
The filing explicitly lists 'Election of Directors' and 'Appointment of Certain Officers' as items being reported, suggesting new individuals may have joined the board or management team.
What is the nature of the compensatory arrangements being disclosed?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item, indicating that details regarding compensation for key personnel are being disclosed.
When was the earliest event reported in this 8-K?
The earliest event reported in this 8-K filing was on December 12, 2025.
What is the company's state of incorporation and principal executive office address?
Relmada Therapeutics, Inc. is incorporated in Nevada and its principal executive offices are located at 2222 Ponce de Leon Blvd., 3rd Floor, Coral Gables, FL 33134.
Filing Stats: 1,161 words · 5 min read · ~4 pages · Grade level 11.5 · Accepted 2025-12-15 07:50:18
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share RLMD The NASDAQ
- $787,787 — r. Traversa's salary will increase from $787,787 to $827,176 per year. Paul Kelly, Chi
- $827,176 — s salary will increase from $787,787 to $827,176 per year. Paul Kelly, Chief Operating
- $499,800 — Mr. Kelly's salary will increase from $499,800 to $524,790 per year. In the event of
- $524,790 — s salary will increase from $499,800 to $524,790 per year. In the event of termination
- $558,990 — r. Shenouda's salary will increase from $558,990 to 586,940 per year. In the event of
- $548,990 — Mr. Ence's salary will increase from $548,990 to $576,440 per year. 1 In the event
- $576,440 — s salary will increase from $548,990 to $576,440 per year. 1 In the event of terminat
Filing Documents
- ea0269660-8k_relmada.htm (8-K) — 40KB
- ea026966001ex10-1_relmada.htm (EX-10.1) — 64KB
- ea026966001ex10-2_relmada.htm (EX-10.2) — 62KB
- ea026966001ex10-3_relmada.htm (EX-10.3) — 65KB
- ea026966001ex10-4_relmada.htm (EX-10.4) — 63KB
- ex10-1_001.jpg (GRAPHIC) — 14KB
- ex10-2_001.jpg (GRAPHIC) — 14KB
- ex10-3_001.jpg (GRAPHIC) — 14KB
- ex10-4_001.jpg (GRAPHIC) — 14KB
- 0001213900-25-121461.txt ( ) — 603KB
- rlmd-20251212.xsd (EX-101.SCH) — 3KB
- rlmd-20251212_lab.xml (EX-101.LAB) — 33KB
- rlmd-20251212_pre.xml (EX-101.PRE) — 22KB
- ea0269660-8k_relmada_htm.xml (XML) — 4KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1* Amended and Restated Employment Agreement, effective as of January 1, 2026, between Relmada Therapeutics, Inc. and Sergio Traversa 10.2* Amended and Restated Employment Agreement, effective as of January 1, 2026, between Relmada Therapeutics, Inc. and Paul Kelly 10.3* Amended and Restated Employment Agreement, effective as of January 1, 2026, between Relmada Therapeutics, Inc. and Maged Shenouda 10.4* Amended and Restated Employment Agreement, effective as of January 1, 2025, between Relmada Therapeutics, Inc. and Charles Ence 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Furnished herewith 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 15, 2025 RELMADA THERAPEUTICS, INC. By: /s/ Sergio Traversa Name: Sergio Traversa Title: Chief Executive Officer 3